Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 16, 2019

Primary Completion Date

November 26, 2021

Study Completion Date

November 26, 2021

Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

allo-APZ2-EB

intravenous infusion of allo-APZ2-EB

Trial Locations (6)

5020

EB-Haus Austria; Salzburger Landeskliniken (SALK); Paracelsus Medizinische Privatuniversität Salzburg (PMU), Salzburg

55455

University of Minnesota, Masonic Cancer Center and Medical Center, Minneapolis

75010

Hôpital Saint-Louis; Département de dermatologie, Paris

79104

Department of Dermatology, Medical Center-University of Freiburg, Freiburg im Breisgau

SE1 9RT

King's College London; St John's Institute of Dermatology;, London

WC1N 3JH

Great Ormond Street Hospital; Dermatology Department, London

All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

collaborator

Granzer Regulatory Consulting & Services

OTHER

collaborator

Ticeba GmbH

INDUSTRY

lead

RHEACELL GmbH & Co. KG

INDUSTRY